跳至主要内容
临床试验/NCT01398592
NCT01398592已完成4 期

Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus®/Eucreas®) and Sitagliptin (Januvia®/Janumet®) After Two Weeks

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 187 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
187
试验地点
1
主要终点
demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with Sitagliptin

研究概览

简要总结

This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatment on top of metformin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with type 2 diabetes 18 to 85 years Metformin monotherapy > 4 weeks HbA1c 6.5 - 9.5%

排除标准

  • FPG > 270 mg/dl Use of other antidiabetic drugs than metformin major cardiovascular event in the last 6 months (MI, stroke...)

研究组 & 干预措施

Vildagliptin

Experimental

Experimental

干预措施: Vildagliptin (Drug)

Sitagliptin

Active Comparator

Active comparator (drug)

干预措施: Sitagliptin (Drug)

结局指标

主要结局

demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with Sitagliptin

时间窗: 14 days

Fasting Plasma Glucose measured on day 14.

次要结局

  • To assess the difference in FPG between vildagliptin and sitagliptin in patients with type 2 diabetes mellitus on concomitant treatment with metformin(14 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Vildagliptin Versus Sitagliptin - Differences in... | 临床试验